<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01031849</url>
  </required_header>
  <id_info>
    <org_study_id>HCSKAL-2009-01</org_study_id>
    <secondary_id>2009-016090-14</secondary_id>
    <nct_id>NCT01031849</nct_id>
  </id_info>
  <brief_title>Analysis of Changes in Adipose Tissue of Patients With Lipoatrophy HIV Infection Treated With Nucleoside Thymidine, After Switching to Monotherapy With Lopinavir / Ritonavir</brief_title>
  <acronym>BIOKAL</acronym>
  <official_title>Análisis de Los Cambios en el Tejido Adiposo de Pacientes Con infección VIH y Lipoatrofia en Tratamiento Con análogos de nucleósidos timidínicos, Tras el Cambio a Monoterapia Con Lopinavir/Ritonavir</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ines Perez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital San Carlos, Madrid</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to analyse the changes in the adipose tissue hystological features and the
      adipogenesis gene expression and related to inflammation after 48 and 96 weeks after the
      change from AZT+3TC+ABC (Trizivir®) to a monotherapy treatment with LPV/r (Kaletra®)
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    patient sample not reached
  </why_stopped>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in those representative gene expression of adipose tissue toxicity (variable established from those gene involved in adipogenesis, inflammation and metabolism. This gene expression will counted)</measure>
    <time_frame>48 and 96 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in physical fat deposits</measure>
    <time_frame>Baseline, 24, 48, 72 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in leptine and adiponectine plasma levels</measure>
    <time_frame>baseline, 24, 48, 72 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients percentage with virologic response (ARN-VIH&lt; 50 copies/mL)</measure>
    <time_frame>48 and 96 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Kaletra, all patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will change actual treament for monotherapy LPV/r. They only will take Kaletra 2/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kaletra</intervention_name>
    <description>Each tablet of Kaletra contains 200 mg of Lopinavir and 50mg of ritonavir. The patients will take two tablets of Kaletra bid.</description>
    <arm_group_label>Kaletra, all patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients infected with VIH-1, documented with a positive HIV-1 antibody test and/or
             positive PCR, confirmed for HIV-1 RNA.

          -  Patients treated with a HAART that should contain AZT+3TC+ABC (Trizivir®)

          -  Patients with an indetectable viral load, which will be defined &lt;40 copies/mL within
             the last six months.

          -  Patients with a lipoatrophy clinical evidence (which will be defined as moderate or
             severe, according to the Lipodystrophy Severity Grading Scale).

          -  Men or women aged ≥ 18.

          -  For women of childbearing potential, negative urine pregnancy test during the
             Screening visit.

          -  Patients that have signed and dated the Informed consent Form prior to any
             Study-specific procedure.

        Exclusion Criteria:

          -  Patients with evidence of protease inhibitors failure, and/or documented evidence of
             protease gene resistance mutation. This evidence could be prior or during the
             inclusion period in the Study.

          -  Patients who, for any reason could not be treated with LPV/r.

          -  Cachexia, defined as an Body Mass Index &lt;17 Kg/m2.

          -  Pregnant or breastfeeding women, or women of childbearing potential who do not use the
             appropriate contraceptive method, according to the Investigator judgment.

          -  Clinically relevant disease or condition, according to the Investigator judgment,
             three months prior to the patient inclusion in the Study.

          -  Patients taking the following concomitant medication that could affect the adipocyte
             function or morphology, such as: insulin, steroids, anabolic steroid,
             anti-inflammatory medication for more than three months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vicente Estrada, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>hospital Clínico San Carlos, Madrid</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2009</study_first_submitted>
  <study_first_submitted_qc>December 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2009</study_first_posted>
  <last_update_submitted>April 5, 2013</last_update_submitted>
  <last_update_submitted_qc>April 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital San Carlos, Madrid</investigator_affiliation>
    <investigator_full_name>Ines Perez</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>HIV 1 patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

